Inquiry Basket
BOC Sciences offers comprehensive one-stop antibody-drug conjugate research and evaluation services.
BOC Sciences provides customers with comprehensive one-stop services for all aspects of antibody-drug conjugate research and evaluation, from antibody modification and conjugation, cytotoxin development, cytotoxin-linker synthesis, ADC manufacturing, to ADC characterization and evaluation various stages.
Jun 29, 2024
Kadcyla, also known as Trastuzumab Emtansine, is a breakthrough drug for the treatment of breast cancer. This innovative drug is a targeted therapy that combines the efficacy of two well-known anticancer drugs, Trastuzumab and Emtansine, to specifically target and destroy cancer cells that overexpress human epidermal growth factor receptor 2 (HER2).
Aug 30, 2024
In 2023, the ADC market size will exceed $10 billion for the first time, with at least five ADC drugs having annual sales exceeding $1 billion. Among them, Enhertu has achieved great success, with a significant sales growth rate. Polivy, Adcetris, Trodelvy, Tivdak and Padcev also have obvious growth rates.
